Madrigal Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Paulson & Co. Inc. has filed a Schedule 13G reporting beneficial ownership of 6.1% of Madrigal Pharmaceuticals, Inc. common stock.
NASDAQ
Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 8.8% of Madrigal Pharmaceuticals, Inc. common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has reported a 0% beneficial ownership in Madrigal Pharmaceuticals Inc. following an internal realignment.
NASDAQ
Janus Henderson Group plc has disclosed an 8.3% beneficial ownership stake in Madrigal Pharmaceuticals, Inc., holding 1,842,690 common shares.
NASDAQ
Janus Henderson Group plc has disclosed an increased beneficial ownership of 9.9% in Madrigal Pharmaceuticals, Inc. common stock as of June 30, 2025.
NASDAQ
SCHEDULE 13G/A: Janus Henderson Group PLC Discloses 10.0% Passive Stake in Madrigal Pharmaceuticals, Inc.
Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 10.0% beneficial ownership stake in Madrigal Pharmaceuticals, Inc. as of March 31, 2025.
NASDAQ
Janus Henderson Group plc has filed an amended Schedule 13G, revealing a 10.1% beneficial ownership stake in Madrigal Pharmaceuticals, Inc. as of December 31, 2024.